Management of rheumatoid arthritis (RA) has evolved over the years as a result of better understanding of the role of different therapeutic strategies, as well as following an increasing availability of new disease-modifying antirheumatic drugs. However, the role of patients in sharing decisions, as well as the rules informing precision medicine or the principles to follow in case of specific comorbidities or extra-articular manifestations are still areas for improvement. Moreover, in 2020, the novel Coronavirus disease-19 outbreak has completely changed many attitudes in terms of assessment and treatment paradigms in most clinical diseases, including RA. In this narrative review, the authors report their specific point of view on the management of RA, based on a critical revision of literature published in 2020, focusing on relevant novelties and future research directions.

Silvagni, E., Sakellariou, G., Bortoluzzi, A., Giollo, A., Ughi, N., Vultaggio, L., et al. (2021). One year in review 2021: Novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39(4), 705-720.

One year in review 2021: Novelties in the treatment of rheumatoid arthritis

Scire C. A.
Ultimo
2021

Abstract

Management of rheumatoid arthritis (RA) has evolved over the years as a result of better understanding of the role of different therapeutic strategies, as well as following an increasing availability of new disease-modifying antirheumatic drugs. However, the role of patients in sharing decisions, as well as the rules informing precision medicine or the principles to follow in case of specific comorbidities or extra-articular manifestations are still areas for improvement. Moreover, in 2020, the novel Coronavirus disease-19 outbreak has completely changed many attitudes in terms of assessment and treatment paradigms in most clinical diseases, including RA. In this narrative review, the authors report their specific point of view on the management of RA, based on a critical revision of literature published in 2020, focusing on relevant novelties and future research directions.
Articolo in rivista - Review Essay
Biological agents; Disease-modifying anti-rheumatic drugs; JAK inhibitors; Precision medicine; Rheumatoid arthritis;
English
2021
39
4
705
720
open
Silvagni, E., Sakellariou, G., Bortoluzzi, A., Giollo, A., Ughi, N., Vultaggio, L., et al. (2021). One year in review 2021: Novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39(4), 705-720.
File in questo prodotto:
File Dimensione Formato  
article (15).pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 494.33 kB
Formato Adobe PDF
494.33 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/328912
Citazioni
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 16
Social impact